By Josh Beckerman

Adagio Therapeutics Inc. discussed its efforts related to the Omicron Covid-19 variant, including engaging with the U.S. Food and Drug Administration on potential protocol updates to its global Phase 2/3 clinical trials of ADG20. Updates may include a higher dose.

The company said is pausing enrollment of new patients in the 300-mg dose arm in two clinical trials as it updates protocols.

Adagio also "summarized recent findings reported in three separate publications" that show ADG20, its lead monoclonal antibody, "has neutralization activity against" the Omicron variant.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 12, 2022 17:37 ET (22:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Adagio Therapeutics Charts.
Adagio Therapeutics (NASDAQ:ADGI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Adagio Therapeutics Charts.